Phase 4 Rare Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are currently receiving dabrafenib, trametinib, or both as part of an existing Novartis or former GSK-sponsored study that has already met its main research goals.
- People whose treating doctor believes they would benefit from continuing this treatment.
Who may not be able to join:
- People who were permanently taken off the study treatment in their original (parent) study.
- People whose condition is one for which dabrafenib and/or trametinib is already commercially available and covered by health insurance or a government reimbursement program in their country.
- People who currently have unresolved side effects that caused their dabrafenib and/or trametinib doses to be paused or stopped in their original study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Occurences of adverse events to evaluate long term safety and tolerability of dabrafenib, trametinib or combination
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.